New hope for Hard-to-Treat prostate cancer: enhertu trial launches
NCT ID NCT06610825
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests Enhertu, a targeted drug, in 60 men with HER2-positive prostate cancer that has spread and stopped responding to hormone therapy and newer drugs like abiraterone. Participants must have tried or refused chemotherapy. The study measures tumor shrinkage and how long the cancer is controlled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Enhertu (fam-trastuzumab deruxtecan-nxki)
What this could lead to
If it works, this could offer a new treatment option for men with HER2-positive prostate cancer that has stopped responding to hormone therapy and chemotherapy.
What could go wrong
This is a small, early-phase trial with only 60 people, so results may not apply to everyone. Enhertu can cause serious side effects like lung inflammation or heart problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Washington DC VAMC
RECRUITINGWashington D.C., District of Columbia, 20422, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact